Australia's Telix Pharmaceuticals hits record high on strong quarter

Hanall Biopharma

18/04/2024 01:36

** Shares of Telix Pharmaceuticals  TLX.AX  jump as much as
15.3% to A$13.25 to hit a record high 
    ** Stock emerges as top gainer on the benchmark index 
    ** The biopharma co reports an 18% rise in quarterly revenue
on prior quarter too $114.9 mln, driven by sales of its prostate
cancer imaging product Illuccix
    ** Co reaffirms FY revenue between $445 mln to $465 mln 
    ** Shares poised to see their best day since July 21, 2022 -
if current trend holds 
    ** Stock has risen 24.4% this year as of last close

 (Reporting by Archishma Iyer)
 ((Archishma.Iyer@thomsonreuters.com;))